CAS: 34915-68-9; 2-[3-(Tert-Butylamino)-2-Hydroxypropoxy]Benzonitrile

该化合物是一个乙型阻塞器,具有乙型对抗剂和局部抗药性,主要用于管理高血压和某些心脏状况,其特点是能够有选择地堵塞主要位于心脏中的乙型-1肾上腺受体,导致心率和心肌内皮接触性下降.该复合物显示出一种种族混合物,即它含有两种抗体的相等部分,可产生不同的药理效应.Bunterolol通常以口服方式施用,而且已知其半衰期相对较长,允许在临床环境中每天一次施用.其化学结构包括苯丙基氢氧基化合物组和二类矿,有助于其药理活动.此外,Bunitrool可能有一些内在的血压性活性,可以影响其整体心血管效应.与其他乙型阻塞剂一样,潜在的副作用可能包括疲劳,眩晕和胸腔,在病人呼吸状况中应谨慎使用.

结构式图片

上下游产品

CAS号38465-16-6 2-(2,3-环氧丙氧基)苯腈

合成工艺路线路线简述

    📜2-(2,3-环氧丙氧基)苯腈置于溶剂黄146,三乙胺,Lithium Chloride体系中,用 四氢呋喃,乙醇 用作溶剂,化学反应 22.0H,反应生成布诺洛尔
    参考文献:高效化学合成(rs)-,(R)-和(S)-Bunitrolol
    标题:高效化学合成(rs)-,(R)-和(S)-Bunitrolol
    摘要:摘要 据报道,β-肾上腺素能受体阻断剂苯尼洛尔是一种新的化学方法,也是第一个化学酶法合成,呈外消旋(rs)和对映体富集形式(r和s).中间体(R)-和(S)-1-氯-3-(2-氰基苯氧基)丙-2-醇中间体是通过酶动力学拆分由相应的外消旋醇合成的.市售脂肪酶ps-C和ccl在外消旋醇与乙酸乙烯酯的酯交换过程中表现出互补的对映选择性,提供(R)-醇与(S)-乙酸酯和(S)-醇与(R))-乙酸盐,分别代表用于逆转对映选择性的酶促开关的一个例子.优化了温度,时间,底物和酶的浓度以及反应介质等各种反应参数对活性和对映选择性的影响.通过用叔丁胺处理,将(R)-和(S)-醇分别转化为(S)-和和(R)-布尼特洛尔.酶法获得的(R)-和(S)-乙酸盐通过化学水解脱乙酰基化为相应的醇,并进一步转化为(S)-和(R)-Bunitrolol通过化学方法.这是该药物的两种对映异构体的首次化学合成.(rs)-,(-
    Doi:10.1055/s-0033-1340465

    海关参考信息

    专利信息


    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-2008287407-A1
    优先权日:2003-12-10
    标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
    发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
    权利人:NITROMED INC
    摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

    专利号:US-7708989-B2
    优先权日:1999-10-29
    标题 :Methods of treating vascular diseases characterized by nitric oxide insufficiency
    发明人:LOSCALZO JOSEPH; VITA JOSEPH A; LOBERG MICHAEL D; WORCEL MANUEL
    权利人:NITROMED INC
    摘要:The invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor, and optionally at least one compound used to treat cardiovascular diseases and/or at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The vascular diseases characterized by nitric oxide insufficiency include a cardiovascular disease and a disease resulting from oxidative stress.

    专利号:US-7384976-B2
    优先权日:2001-05-02
    标 题:Nebivolol and its metabolites in combination with nitric oxide donors, compositions and methods of use
    发明人:GARVEY DAVID S
    权利人:NITROMED INC
    摘要:The invention describes novel compositions comprising nebivolol and/or at least one metabolite of nebivolol and at least one nitric oxide donor, and, optionally, at least one antioxidant or a pharmaceutically acceptable salt thereof, and/or at least one compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof, and/or at least one nitrosated compound used to treat cardiovascular diseases. The compounds and compositions of the invention can also be bound to a matrix. The nitric oxide donor is a compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The invention also provides methods for treating and/or preventing vascular diseases characterized by nitric oxide insufficiency; and for treating and/or preventing Raynaud's syndrome; and for treating and/or preventing cardiovascular diseases or disorders.

    专利号:US-2008214827-A1
    优先权日:2004-02-03
    标 题:Synthesis of Cyanoimino-Benzoimidazoles
    发明人:GOEHRING R RICHARD; WHITEHEAD JOHN; SHAO BIN
    权利人:EURO CELTIQUE SA
    摘要:Disclosed in certain embodiments is a process for synthesizing a compound of formula (V) and salts thereof.

    专利号:US-7235237-B2
    优先权日:1999-10-29
    标 题 :Methods of treating vascular diseases characterized by nitric oxide insufficiency
    发明人:LOSCALZO JOSEPH; VITA JOSEPH A; LOBERG MICHAEL D; WORCEL MANUEL
    权利人:NITROMED INC
    摘要:The present invention provides methods of treating or preventing vascular diseases caused by nitric oxide (NO) insufficiency. The methods encompass administering a composition comprising an antioxidant, a compound to treat cardiovascular diseases, a nitrosated compound, a compound that donates, transfers or relases NO, or is a NO synthase substrate, or endogenously stimulates NO synthesis, or stimulates levels of endothelium derived relaxing factor. In the said composition, a hydralazine compound may be an antioxidant, isosorbide mono-or dinitrate may be the compound to donate, transfer, release, or stimulate endogenous NO synthesis. The isorsorbide may also elevate endogenous levels of endotherlium-derived relaxing factor, or be a NO synthase substrate and angiotensin enzyme inhibitor may be nitrosated compound. Disclosed in the invention is also a method to treat, or prevent Renaud's syndrome by administering a therapeutically effective amount of an antioxidant, a NO donor, a nitrosated compound and novel sustained-release formulations (e.g. a transdermal patch).

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Shimamoto Y, Watanabe K, Ikadai H, Okamura M, Ishizuka M. Repression of hepatic cytochrome P450 2D expression in mice during Babesia microti infection. J Vet Med Sci. 2014 Aug;76(8):1147-51. doi: 10.1292/jvms.14-0109. Epub 2014 May 1.
    2: Schubert B, Oberacher H. Impact of solvent conditions on separation and detection of basic drugs by micro liquid chromatography-mass spectrometry under overloading conditions. J Chromatogr A. 2011 Jun 3;1218(22):3413-22. doi: 10.1016/j.chroma.2011.03.051. Epub 2011 Mar 27. 99(10):4406-26. doi: 10.1002/jps.22136. 30(5):505-12. doi: 10.1007/s11259-006-3213-8. 18(3):167-76. doi: 10.1002/chir.20246. 48(22):6970-9. doi: 10.1021/jm050529c. 18(1):79-85. doi: 10.2133/dmpk.18.79. 53(4):289-99. Polish. 11(8):709-18. doi: 10.1097/00008571-200111000-00010. 24(9):988-94. doi: 10.1248/bpb.24.988. 29(12):1203-12. doi: 10.1080/004982599237886. 20(2):85-90. doi: 10.1002/(sici)1099-081x(199903)20:2<85::aid- bdd159>3.0.co;2-3. 11(1):1-9. doi: 10.1002/(SICI)1520-636X(1999)11:1<1::AID-CHIR1>3.0.CO;2-E. 124(3):503-8. doi: 10.1093/oxfordjournals.jbchem.a022141. 8(1):73-82. doi: 10.1097/00008571-199802000-00010. 123(1):162-8. doi: 10.1093/oxfordjournals.jbchem.a021905. 27(11):1121-9. doi: 10.1080/004982597239886. 282(3):1435-41. 48(11):1185-9. doi: 10.1111/j.2042-7158.1996.tb03918.x. 19(11):1429-33. doi: 10.1248/bpb.19.1429.

    合成参考文献


    摘要:European Journal of Pharmacology., 17(341), 1972 []
    摘要:S72 | NTUPHTW | Pharmaceutically Active Substances from National Taiwan University | DOI:10.5281/zenodo.3955664
    参考文献:10.1007/s11259-006-3213-8
    摘要:Ishizuka M, Lee JJ, Masuda M, Akahori F, Kazusaka A, Fujita S. CYP2D-related Metabolism in Animals of the Canoidea Superfamily – Species Differences. Veterinary Research Communications. 2006 Jul;30(5):505–12. doi: 10.1007/s11259-006-3213-8.
    参考文献:10.2165/00003495-199300462-00007
    摘要:Fagard R, Staessen J, Thijs L, Amery A. Influence of antihypertensive drugs on exercise capacity. Drugs. 1993;46 Suppl 2():32–6. doi: 10.2165/00003495-199300462-00007.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知